ERBB2 and breast carcinoma: To better understand how genomic evolution may contribute to metastatic progression in commonly used GEMMs and to compare them to the expanding clinical data, we have extended our previous work to include two additional models of breast cancer metastasis, the C3(1)TAg and MMTV-Myc models, and expanded on the previously analyzed MMTV-Her2 model.